Phase 3 N=108 A Study for Leukemia Patients With Life-Threatening Infections
Leukemia
Primary: Number of Participants Alive at Day 30 — 31; 39 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=29 Clofarabine Bone Marrow Cytoreduction
Leukemia
Primary: Cytoreductive Response — 52 percentage of participants
Phase 2 N=44 Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease
Alzheimer's Disease
Primary: Adverse Events (AEs) by Body System — 5; 2; 6; 5 Adverse Events
N/A N=100 Leukocyte Function in Chronic Obstructive Pulmonary Disease (COPD)
COPD · Emphysema · Chronic Bronchitis
Primary: Effective Concentration (EC 50) of GRO Alpha — 1.5; 0.9; 0.6 ng/ml — p=0.05
Phase 2 N=77 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Biphenotypic Leukemia · Acute Leukemia of Ambiguous Lineage
Primary: Chronic GVHD — 17; 20; 14; 17 Participants
Phase 2 N=32 Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients
Leukemia
Primary: Number of Participants (With Increase) Immune Response to GM-CSF With a Pneumococcal Vaccine — 0; 0; 1; 1 participants
Phase 3 N=114 Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)
Neutropenia · Infection
Primary: Percentage of Participants Who Are Alive at 42 Days After Treatment and Have Had Microbial Response — 42.9; 41.7 percentage of participants — p=0.73
Phase 2 N=29 Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
T-LGL Lymphoproliferative Disorders
Primary: Number of Participants With Hematological Response After Three Months of Alemtuzumab — 15 Participants